Study of SHR-8068 Combined With Adebrelimab and Platinum-containing Chemotherapy in the Treatment of Advanced Gastric and Esophageal Cancer
NCT06247956 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 153
Last updated 2025-09-03
Summary
Objective response rate (ORR) was evaluated to evaluate the efficacy of SHR-8068 combined with adebrelimab and platinum-containing chemotherapy in first-line treatment of advanced gastric and esophageal cancer.
Conditions
- Advanced Gastric Adenocarcinoma and Esophageal Squamous Cell Carcinoma
Interventions
- DRUG
-
SHR-8068;Adebrelimab;Oxaliplatin;Capecitabine Tablets;Paclitaxel Injection;Cisplatin Injection
SHR-8068: Specified dose on specified days. Adebrelimab: Specified dose on specified days. Oxaliplatin: Specified dose on specified days. Capecitabine Tablets: Specified dose on specified days. Paclitaxel Injection: Specified dose on specified days. Cisplatin Injection: Specified dose on specified days.
- DRUG
-
Adebrelimab;Oxaliplatin;Capecitabine Tablets;Paclitaxel Injection;Cisplatin Injection
Adebrelimab: Specified dose on specified days. Oxaliplatin Injection: Specified dose on specified days. Capecitabine Tablets: Specified dose on specified days. Paclitaxel Injection: Specified dose on specified days. Cisplatin Injection: Specified dose on specified days.
Sponsors & Collaborators
-
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
lead INDUSTRY
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- FACTORIAL
Eligibility
- Min Age
- 18 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-03-11
- Primary Completion
- 2025-12-30
- Completion
- 2025-12-30
Countries
- China
Study Locations
More Related Trials
-
Ph1b/2 Study of the Safety and Efficacy of SHR-A1811 Combinations in Advanced HER2 Expression Gastric Cancer
NCT05671822 ·Status: RECRUITING ·Phase: PHASE2
-
Adebrelimab Combined With Nab-paclitaxel, Oxaliplatin and Tegafur (AOS) for Perioperative Treatment of Locally Advanced Resectable GC/GEJ
NCT06808971 ·Status: RECRUITING ·Phase: PHASE2
-
Neoadjuvant Adebrelimab + DOS in Locally Advanced Resectable Gastric Cancer
NCT06475417 ·Status: RECRUITING ·Phase: PHASE2
-
A Clinical Study To Evaluate Camrelizumab (SHR-1210) Plus Capecitabine and Oxaliplatin Followed by Sequential Treatment With Camrelizumab Plus Apatinib Mesylate in Advanced or Metastatic Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJ) Without Prior Systemic Therapy
NCT03813784 ·Status: COMPLETED ·Phase: PHASE3
-
A Phase Ib/II Study of Adebrelimab in Combination with Capecitabine and Oxaliplatin in Cancer
NCT06776770 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Clinical Study of Adebrelimab Combined With Apatinib and Paclitaxel in Patients With Advanced Gastric Cancer.
NCT06339216 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
SHR-A1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on or After First-line Anti-HER2 Therapy-containing Regimen
NCT06123494 ·Status: RECRUITING ·Phase: PHASE3
-
Perioperative Chemotherapy Plus Toripalimab for dMMR Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma
NCT05729646 ·Status: RECRUITING ·Phase: PHASE2
-
Establishment of Precision Targeted Therapy Strategies for Advanced Gastric Cancer Based on Novel Molecular Subtyping
NCT06881017 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
RC48 Combined With Adebrelimab, Apatinib and S-1 as Neoadjuvant Therapy in Locally Advanced Gastric Cancer
NCT06385873 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
A Study of Paclitaxel Combined With Apatinib and Adebrelimab in Gastric/Gastroesophageal Junction Adenocarcinoma
NCT06415669 ·Status: RECRUITING ·Phase: PHASE2
-
SOX Regimen as Neoadjuvant Chemotherapy for AJCC Stage II-III Gastric Cancer
NCT01583361 ·Status: UNKNOWN ·Phase: PHASE3
-
A Study of Ramucirumab in Participants With Gastric or Gastroesophageal Junction Adenocarcinoma
NCT02539225 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction Adenocarcinoma
NCT07102901 ·Status: RECRUITING ·Phase: PHASE2
-
Efficacy and Safety of IMAB362 in Combination With the EOX Regimen for CLDN18.2-positive Gastric Cancer
NCT01630083 ·Status: COMPLETED ·Phase: PHASE2
-
Taxanes or Platinum in Combination With Capecitabine Followed by Capecitabine Alone as First Line Treatment for Patients With Advanced Adenocarcinoma of Stomach or Esophagogastric Junction
NCT01468389 ·Status: UNKNOWN ·Phase: PHASE3
-
Adebrelimab Combined With SOX Regimen in Preoperative Neoadjuvant Transformation Therapy for Locally Advanced Gastric Adenocarcinoma
NCT06192186 ·Status: RECRUITING ·Phase: PHASE4
-
Adebrelimab Combined With Famitinib and Irinotecan in Advanced Gastric Cancer After Failure of First-Line Therapy
NCT07309185 ·Status: RECRUITING ·Phase: PHASE2
-
Adebrelimab and Fruquintinib Combined With Paclitaxel/Albumin Paclitaxel for Advanced Gastric Cancer After PD-1 Antibody Failed
NCT06102759 ·Status: RECRUITING
-
The Combination of Adebrelimab, Apatinib, and Lrinotecan Liposome for Second-line Treatment of Advanced Gastric Cancer
NCT06592287 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric Cancer
NCT04208347 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2/PHASE3
-
SHR-1210 Combined With Trastuzumab , Oxaliplatin and Capecitabine for Neoadjuvant Therapy of Gastric Adenocarcinoma/Gastroesophageal Junction Adenocarcinoma
NCT03950271 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Peri-operative Sintilimab in Combination With SOX in Locally Advanced Gastric Cancer
NCT04982939 ·Status: UNKNOWN ·Phase: PHASE2
-
The Comparison of XELOX and EOX in the First-line Treatment of Advanced Gastric Cancer
NCT02395640 ·Status: COMPLETED ·Phase: PHASE3
-
A Phase II Trial of Perioperative Adebrelimab Combined With XELOX in Resectable Locally Advanced Gastric/Gastroesophageal Junction Cancer (GC/GEJC)
NCT06506292 ·Status: RECRUITING ·Phase: PHASE2